2022
Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease
Mosher CL, Nanna MG, Jawitz OK, Raman V, Farrow NE, Aleem S, Casaburi R, MacIntyre NR, Palmer SM, Myers ER. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Network Open 2022, 5: e2218189. PMID: 35731514, PMCID: PMC9218844, DOI: 10.1001/jamanetworkopen.2022.18189.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyNet cost savingsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness ratioEconomic evaluationSocietal perspective analysisCost savingsSensitivity analysisChronic obstructive pulmonary diseaseMarkov microsimulation modelUS dollarsMicrosimulation modelNet costDominant strategySocietal perspectiveLifetime horizonUS health care systemPulmonary rehabilitationObstructive pulmonary diseaseCOPD hospitalizationsHypothetical cohortQALYSavingsMicrosimulation
2021
The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial
Nanna MG, Vemulapalli S, Fordyce CB, Mark DB, Patel MR, Al-Khalidi HR, Kelsey M, Martinez B, Yow E, Mullen S, Stone GW, Ben-Yehuda O, Udelson JE, Rogers C, Douglas PS. The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. American Heart Journal 2021, 245: 136-148. PMID: 34953768, PMCID: PMC8979644, DOI: 10.1016/j.ahj.2021.12.004.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable chest painChest painDiagnostic strategiesUsual careCardiac symptomsMajor adverse cardiac eventsNon-acute chest painObstructive coronary artery diseaseInitial diagnostic strategyInvasive cardiac catheterizationUse of CCTAUsual care strategyAdverse cardiac eventsProspective randomized trialsClinical care teamFractional flow reserveQuality of lifeHealth care costsOptimal evaluationPrimary endpointRevascularization TrialSecondary endpointsCardiac eventsArtery disease